KRAS and chronic myelogenous leukemia, BCR-ABL1 positive: CSCs resistant to KRAS-targeting therapy in the PDAC context, as well as leukemic stem cells (LSCs) resistant to BCR-ABL-targeting in chronic myeloid leukemia (CML), were found to express an OXPHOS phenotype [102,103].